Free Trial

Insider Selling: Cardlytics (NASDAQ:CDLX) CEO Sells 7,799 Shares of Stock

Cardlytics logo with Business Services background

Key Points

  • Amit Gupta, CEO of Cardlytics, sold 7,799 shares at an average price of $2.27, reducing his ownership by 1.54% and maintaining 498,310 shares valued at approximately $1.13 million.
  • Cardlytics shares increased by 0.4%, reaching $2.37, with a current market capitalization of $126.18 million, while experiencing a price-to-earnings ratio of -0.65.
  • Institutional investors own 68.10% of Cardlytics, with some firms, like Post Resch Tallon Group Inc. and Two Sigma Investments, increasing their stakes in recent quarters.
  • Five stocks to consider instead of Cardlytics.

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Amit Gupta sold 7,799 shares of the company's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $2.27, for a total transaction of $17,703.73. Following the completion of the transaction, the chief executive officer owned 498,310 shares in the company, valued at approximately $1,131,163.70. This represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Amit Gupta also recently made the following trade(s):

  • On Tuesday, August 19th, Amit Gupta sold 68,685 shares of Cardlytics stock. The stock was sold at an average price of $1.12, for a total transaction of $76,927.20.
  • On Monday, August 18th, Amit Gupta sold 68,260 shares of Cardlytics stock. The stock was sold at an average price of $1.12, for a total transaction of $76,451.20.

Cardlytics Stock Up 0.4%

Shares of NASDAQ:CDLX traded up $0.01 during trading hours on Thursday, reaching $2.37. The stock had a trading volume of 3,685,673 shares, compared to its average volume of 13,037,717. Cardlytics, Inc. has a 1 year low of $0.85 and a 1 year high of $5.24. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.16 and a current ratio of 1.16. The stock has a market capitalization of $126.18 million, a price-to-earnings ratio of -0.65 and a beta of 1.45. The firm's 50 day moving average is $1.58 and its 200-day moving average is $1.73.

Institutional Trading of Cardlytics

Institutional investors have recently added to or reduced their stakes in the stock. Post Resch Tallon Group Inc. lifted its position in Cardlytics by 100.0% in the second quarter. Post Resch Tallon Group Inc. now owns 20,000 shares of the company's stock valued at $33,000 after purchasing an additional 10,000 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Cardlytics by 12.5% in the fourth quarter. Two Sigma Investments LP now owns 94,901 shares of the company's stock worth $352,000 after buying an additional 10,508 shares during the period. Two Sigma Advisers LP raised its stake in Cardlytics by 44.1% during the 4th quarter. Two Sigma Advisers LP now owns 36,900 shares of the company's stock valued at $137,000 after purchasing an additional 11,300 shares during the period. ProShare Advisors LLC bought a new stake in Cardlytics in the 4th quarter worth approximately $43,000. Finally, Check Capital Management Inc. CA boosted its holdings in Cardlytics by 20.7% during the 2nd quarter. Check Capital Management Inc. CA now owns 74,500 shares of the company's stock valued at $123,000 after acquiring an additional 12,800 shares during the period. 68.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Evercore ISI reduced their target price on shares of Cardlytics from $3.00 to $2.00 and set an "in-line" rating for the company in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Cardlytics currently has an average rating of "Moderate Buy" and a consensus target price of $2.25.

Read Our Latest Stock Report on Cardlytics

About Cardlytics

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cardlytics Right Now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.